In a cohort of 560 patients suffering from breast cancer, HRDetect could identify and, importantly, discriminate between BRCA1/2-deficient tumors with a sensitivity of 98.7%, using a probabilistic cutoff of 0.7 [62]. This evidence concerns the gene BRCA1 and breast carcinoma.